Navigation Links
Pharmaceutical breakthrough may make a range of drugs cheaper and more available
Date:1/30/2008

A new study published in the February 2008 print edition of The FASEB Journal (www.fasebj.org) describes a scientific advance that should reduce the cost and increase the availability of a wide range of drugs. In the report, University of Pennsylvania researchers describe how they used gene therapy to reduce the time it takes to breed large animals capable of producing therapeutic proteins in their milk, such as insulin or those that fight cancer. This represents a significant milestone in drug development, as current methods involve cloning, which takes more time and generally costs more.

Having an easier way to harness natures power to produce large quantities of specific proteins in milk could increase the availability of drugs for people who could otherwise not afford these treatments, said Ina Dobrinski, one of the researchers on the study.

The study also is significant because it may also be a new way to eliminate diseases in future generations of animals, such as those used for livestock. Heres why: To get the goats to produce specific proteins, the researchers used radiation to kill a portion of a male goats germ cells (the cells that produce sperm). Then they used a modified adeno-associated virus (a well studied and tolerated gene therapy vector) to insert a gene in the remaining cells. Once the new gene took hold in the germ cells, a predictable number of female offspring produced the desired protein in their milk. The advance is immediately valuable for pharmaceutical development and biology research, but a similar approach could be used to bolster the food supply by eliminating genetic disorders in animals over several generations. It is also possible that once perfected, this technique could eliminate disease genes in humans over several generations, assuming ethical concerns can be resolved adequately.

For thousands of years, people have domesticated cows and goats to make milk, b
'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
2. NMR researchers unlock hydrogens secrets to spot polymorphism in pharmaceuticals
3. Biopharmaceutical infrastructure key to lower drug development costs
4. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
5. Bacteria from sponges make new pharmaceuticals
6. Breakthrough research turns the tide on water-borne pathogen
7. Further breakthroughs for breast cancer patients
8. University of Alberta researchers report breakthrough in lowering bad cholesterol, fatty acid levels
9. Genetic breakthrough offers promise in tackling kidney tumors
10. Medical breakthrough for organ transplants and cardiovascular diseases by Flemish researchers
11. Breakthrough technology observes synapse in real time, supporting theory of vesicular recycling
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2
Other Biology Technology:Covaris Installed Instrument Base Reaches 500 Units 2Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission 2Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission 3Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 2Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 3Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 4Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 5Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 6Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 7Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 8Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 9Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 10Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 11Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 12Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 13Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 14Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 15Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 16Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 17